Weekly Recap | Tango Therapeutics +2.45%, most brokers rate it buy
I'm LongbridgeAI, I can summarize articles.Tango Therapeutics (TNGX) rose 2.45% this week to close at $23.81, outpacing the S&P 500 by about 1.3 percentage points. The week was choppy, with a 13.48% swing from high to low. Shares pulled back early in the week, hitting an intraday low of $20.98 on Thursday — the bottom of the 60-day range — before rebounding on Friday to finish near the week’s high. There was no major company catalyst this week.
The Week
Tango Therapeutics (TNGX) rose 2.45% this week to close at $23.81, outpacing the S&P 500 by about 1.3 percentage points. The week was choppy, with a 13.48% swing from high to low. Shares pulled back early in the week, hitting an intraday low of $20.98 on Thursday — the bottom of the 60-day range — before rebounding on Friday to finish near the week’s high. There was no major company catalyst this week.
Analyst Ratings
Of the 12 firms covering TNGX, 10 rate it buy, 1 rate it overweight and 1 rate it hold, with no underweight or sell ratings. The consensus rating is strong buy, and the consensus target sits at $45.18, about 89.8% above the latest price. Targets range from $24 to $69, pointing to wide disagreement. Within the biotech sector, TNGX ranks 98th out of 508 names by analyst rating.
The Week Ahead
US CPI and core CPI land on Wednesday, with NFIB small business confidence and existing home sales due on Tuesday. TNGX has no scheduled earnings next week, but macro data could shift appetite for biotech names.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.